PIA
ALXN

Piedmont Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Piedmont Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-18,396
Closed -$1.65M – 775
2020
Q1 		$1.65M Buy
18,396
+2,160
+13% +$212K 0.07% 232
2019
Q4 		$1.76M Buy
16,236
+650
+4% +$69.5K 0.06% 231
2019
Q3 		$1.53M Buy
15,586
+287
+2% +$32.4K 0.06% 237
2019
Q2 		$2M Sell
15,299
-1,170
-7% -$151K 0.08% 207
2019
Q1 		$2.23M Buy
16,469
+310
+2% +$38.5K 0.09% 202
2018
Q4 		$1.57M Buy
16,159
+1,047
+7% +$124K 0.08% 214
2018
Q3 		$2.1M Buy
15,112
+5,790
+62% +$726K 0.09% 200
2018
Q2 		$1.16M Sell
9,322
-22,944
-71% -$2.68M 0.06% 298
2018
Q1 		$3.6M Sell
32,266
-14,542
-31% -$1.74M 0.1% 217
2017
Q4 		$5.6M Sell
46,808
-154
-0.3% -$18.8K 0.11% 199
2017
Q3 		$6.59M Buy
46,962
+429
+0.9% +$58.3K 0.14% 186
2017
Q2 		$5.66M Buy
46,533
+446
+1% +$51.9K 0.13% 195
2017
Q1 		$5.59M Buy
46,087
+401
+0.9% +$51.7K 0.12% 205
2016
Q4 		$5.59M Buy
45,686
+1,003
+2% +$123K 0.11% 193
2016
Q3 		$5.48M Sell
44,683
-4,619
-9% -$595K 0.12% 191
2016
Q2 		$5.76M Buy
49,302
+914
+2% +$130K 0.12% 185
2016
Q1 		$6.74M Buy
48,388
+744
+2% +$109K 0.14% 158
2015
Q4 		$9.09M Buy
47,644
+421
+0.9% +$73.5K 0.19% 130
2015
Q3 		$7.39M Buy
47,223
+378
+0.8% +$69K 0.17% 144
2015
Q2 		$8.47M Buy
+46,845
New +$8.08M 0.18% 146

Other funds holding ALXN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Piedmont Investment Advisors's ALXN Position: Q2 2020 in Review

Piedmont Investment Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 18,396 shares — an estimated $1.65M sold.

Piedmont Investment Advisors first reported a position in ALXN in Q2 2015 and held it in 20 quarters. The position peaked at $9.09M in Q4 2015. 706 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • Piedmont Investment Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Piedmont Investment Advisors sold 18,396 Alexion Pharmaceuticals shares in Q2 2020, an estimated $1.65M.
  • Piedmont Investment Advisors first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 20 quarters.
  • Piedmont Investment Advisors's Alexion Pharmaceuticals position peaked at $9.09M in Q4 2015.
  • 706 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Piedmont Investment Advisors's 13F filing for Q2 2020.